Our commitment to quality ensures healthcare providers receive reliable tools for critical patient care and drug preparation
Tesamorelin was engineered with a trans-3-hexenoic acid modification that protects it from DPP-IV degradation, extending its half-life from the ~7 minutes of native GHRH to approximately 26 minutes
What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
The peptide upregulates tissue repair genes, downregulates inflammation genes, resets gene expression toward younger patterns, and activates stem cell markers (p63, integrins)
In diabetic models, Caveolin-1 expression is significantly reduced
